Proposed chairman Ulf Wiinberg buys shares in Hansa Medical

Regulatory News:

Ulf Wiinberg has purchased 75,000 shares in Hansa Medical AB (publ) during April 5-6, 2016. He has been nominated by the company’s nomination committee as new chairman of the board. The annual general meeting will be held on May 11.

About Hansa Medical AB

Hansa Medical is a biopharmaceutical company focusing on novel immunomodulatory enzymes. The lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Additional projects focus on development of new antibody modulating enzymes, as well as HBP, a diagnostic biomarker for prediction of severe sepsis at emergency departments that is already introduced on the market. The company is based in Lund, Sweden. Hansa Medical’s share (ticker: HMED) is listed on Nasdaq Stockholm.

This information was brought to you by Cision http://news.cision.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20160406005808/en/